"Acquiring the rights to a mid- or late-stage drug candidate is the focus of many companies in the biotechnology community today. However, the common wisdom holds that there are many suitors pursuing precious few opportunities. This session provides the opportunity to learn how several companies
achieved the elusive goal of in-licensing a late-stage product candidate from pharma on terms that were acceptable to management and shareholders and promised excellent
potential returns to the company and its licensor."

Objective1: Prepare for the main risks and challenges presented by emerging markets.

Objective2: Understand actionable best practices and insights to help build organizational capabilities and improve deal processes.

Objective3: Learn from other industries what contributes to success and failure in emerging markets transactions.